Skip to main content

Apellis Pharmaceuticals Stock Forecast, Price & News

-1.39 (-3.05 %)
(As of 05/14/2021 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume40,227 shs
Average Volume648,816 shs
Market Capitalization$3.56 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive APLS News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Apellis Pharmaceuticals logo

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan. The company was incorporated in 2009 and is based in Waltham, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:APLS
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Book Value$0.46 per share


Net Income$-304,710,000.00




Market Cap$3.56 billion
Next Earnings Date7/30/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.56 out of 5 stars

Medical Sector

482nd out of 2,039 stocks

Pharmaceutical Preparations Industry

227th out of 769 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions

Is Apellis Pharmaceuticals a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 3 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Apellis Pharmaceuticals stock.
View analyst ratings for Apellis Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Apellis Pharmaceuticals?

Wall Street analysts have given Apellis Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Apellis Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Apellis Pharmaceuticals' next earnings date?

Apellis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, July 30th 2021.
View our earnings forecast for Apellis Pharmaceuticals

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) issued its quarterly earnings data on Tuesday, April, 27th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.69) by $0.63.
View Apellis Pharmaceuticals' earnings history

How has Apellis Pharmaceuticals' stock been impacted by Coronavirus?

Apellis Pharmaceuticals' stock was trading at $27.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APLS stock has increased by 64.0% and is now trading at $44.66.
View which stocks have been most impacted by COVID-19

What price target have analysts set for APLS?

15 Wall Street analysts have issued 1 year price objectives for Apellis Pharmaceuticals' stock. Their forecasts range from $39.00 to $875.00. On average, they anticipate Apellis Pharmaceuticals' share price to reach $130.08 in the next twelve months. This suggests a possible upside of 191.3% from the stock's current price.
View analysts' price targets for Apellis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Apellis Pharmaceuticals' key executives?

Apellis Pharmaceuticals' management team includes the following people:
  • Dr. Cedric Francois, Co-Founder, Pres, CEO & Director (Age 49, Pay $987.91k)
  • Dr. Pascal Deschatelets, Co-Founder & Chief Scientific Officer (Age 51, Pay $712.58k)
  • Mr. Alec Machiels J.D., MBA, Co-Founder & Independent Director (Age 48, Pay $61.75k)
  • Mr. Timothy E. Sullivan, Chief Financial Officer (Age 50, Pay $610.65k)
  • Dr. Federico Grossi M.D., Ph.D., Co-Founder & Chief Medical Officer (Age 47)
  • Ms. Nur Nicholson, Chief Technical Operations Officer
  • Ms. Nicole Perry, VP of Accounting & Treasurer (Age 57)
  • Mr. David O. Watson, Gen. Counsel (Age 48)
  • Ms. Karen Lewis, Chief People Officer
  • Dr. Lukas Scheibler M.D., Ph.D., Chief Innovation Officer (Age 50)

What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?

6 employees have rated Apellis Pharmaceuticals CEO Cedric Francois on Cedric Francois has an approval rating of 100% among Apellis Pharmaceuticals' employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Apellis Pharmaceuticals' key competitors?

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.31%), Jennison Associates LLC (3.37%), Victory Capital Management Inc. (2.40%), Geode Capital Management LLC (1.30%), Northern Trust Corp (0.83%) and Compagnie Lombard Odier SCmA (0.48%). Company insiders that own Apellis Pharmaceuticals stock include A Sinclair Dunlop, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Nicole D Perry, Pascal Deschatelets, Timothy Eugene Sullivan and Victoria L Brown.
View institutional ownership trends for Apellis Pharmaceuticals

Which major investors are selling Apellis Pharmaceuticals stock?

APLS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Federated Hermes Inc., Tekla Capital Management LLC, Jennison Associates LLC, Credit Suisse AG, Bank of New York Mellon Corp, Northern Trust Corp, and Algert Global LLC. Company insiders that have sold Apellis Pharmaceuticals company stock in the last year include A Sinclair Dunlop, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Nicole D Perry, Pascal Deschatelets, and Victoria L Brown.
View insider buying and selling activity for Apellis Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Apellis Pharmaceuticals stock?

APLS stock was acquired by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA, Renaissance Technologies LLC, Geode Capital Management LLC, Russell Investments Group Ltd., Rafferty Asset Management LLC, Bank of Montreal Can, TD Asset Management Inc., and Victory Capital Management Inc..
View insider buying and selling activity for Apellis Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $44.66.

How much money does Apellis Pharmaceuticals make?

Apellis Pharmaceuticals has a market capitalization of $3.59 billion. The company earns $-304,710,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis.

How many employees does Apellis Pharmaceuticals have?

Apellis Pharmaceuticals employs 374 workers across the globe.

What is Apellis Pharmaceuticals' official website?

The official website for Apellis Pharmaceuticals is

Where are Apellis Pharmaceuticals' headquarters?

Apellis Pharmaceuticals is headquartered at 100 FIFTH AVENUE, WALTHAM MA, 02451.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The company can be reached via phone at 617-977-5700 or via email at [email protected]

This page was last updated on 5/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.